AUTHOR=Li Yixuan , Rao Maohua , Zheng Chenxi , Huang Jiahui , Fang Danzhou , Xiong Yalan , Yuan Gengbiao 

TITLE=Analysis of factors influencing the clinical outcome after surgery and 131I therapy in patients with moderate-risk thyroid papillary carcinoma

JOURNAL=Frontiers in Endocrinology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.1015798

DOI=10.3389/fendo.2022.1015798

ISSN=1664-2392

ABSTRACT=<sec><title>Purpose</title><p>Generally, the prognosis for papillary thyroid cancer (PTC) is favorable. However, the moderate risk involved warrants further evaluation. Hence, we investigated the clinical outcomes in patients with moderate-risk PTC following surgery and the first <sup>131</sup>I therapy, as well as the relevant factors that influence the therapeutic efficacy.</p></sec><sec><title>Methods</title><p>Retrospective analyses of 175 patients with medium-risk PTC who visited the Second Affiliated Hospital of Chongqing Medical University from September 2017 to April 2019 were conducted. In according with the 2015 American Thyroid Association (ATA) guideline treatment response evaluation system, the patients were categorized into the following groups: excellent response (ER), indeterminate response (IDR), biochemical incomplete response (BIR), and structurally incomplete response (SIR), of which IDR, BIR, and SIR were collectively referred to as the NER group. To compare the general clinical features between the 2 groups of patients, 2 independent samples <italic>t-</italic>tests, <italic>χ<sup>2</sup></italic> test, and Mann–Whitney <italic>U-</italic>test were performed, followed by multivariate logistic regression analyses. With reference to the receiver operating characteristic (ROC) curve, the predicted value of ps-Tg to ER was evaluated, and the best cut-off value was determined. The subgroups with BRAF<sup>V600E</sup> test results were analyzed by <italic>χ</italic>2 test only.</p></sec><sec><title>Results</title><p>The treatment responses of 123 patients were ER, while those of 52 patients were NER. The differences in the maximum tumor diameter (<italic>U =</italic> 2495.50), the amount of metastatic lymph nodes (<italic>U =</italic> 2313.50), the size of metastatic lymph node (<italic>U</italic> = 2113.50), the metastatic lymph node ratio (<italic>U</italic> = 2111.50), metastatic lymph node location (<italic>χ<sup>2</sup></italic> = 9.20), and ps-Tg level (<italic>U =</italic> 1011.00) were statistically significant. Multivariate regression analysis revealed that ps-Tg (OR = 1.209, 95% <italic>CI</italic>: 1.120–1.305) was an independent variable affecting ER. The cut-off value of ps-Tg for predicting ER was 6.915 ug/L, while its sensitivity and specificity were 69.2% and 89.4%, respectively.</p></sec><sec><title>Conclusions</title><p>Patients with smaller tumor size, fewer lymph nodes, lower metastatic lymph node ratio, metastatic lymph nodes in the central region, smaller lymph node size, and ps-Tg &lt;6.915 ug/L demonstrated better therapeutic effects after the initial treatment.</p></sec>